Journal
BIOMACROMOLECULES
Volume 22, Issue 4, Pages 1406-1416Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.biomac.0c01627
Keywords
-
Funding
- Bundesministerium fur Bildung und Forschung [13XP5049A]
Ask authors/readers for more resources
This study explores polyglycerol as an alternative to PEG for extending the half-life of biotherapeutics, showing similar performance between the two in terms of hydrodynamic sizes and binding affinity to therapeutic receptors.
Since several decades, PEGylation is known to be the clinical standard to enhance pharmacokinetics of biotherapeutics. In this study, we introduce polyglycerol (PG) of different lengths and architectures (linear and hyperbranched) as an alternative polymer platform to poly(ethylene glycol) (PEG) for half-life extension (HLE). We designed site-selective N-terminally modified PG-protein conjugates of the therapeutic protein anakinra (IL-1ra, Kineret) and compared them systematically with PEG analogues of similar molecular weights. Linear PG and PEG conjugates showed comparable hydrodynamic sizes and retained their secondary structure, whereas binding affinity to IL-1 receptor 1 decreased with increasing polymer length, yet remained in the low nanomolar range for all conjugates. The terminal half-life of a 40 kDa linear PG-modified anakinra was extended 4-fold compared to the unmodified protein, close to its PEG analogue. Our results demonstrate similar performances of PEG- and PG-anakinra conjugates and therefore highlight the outstanding potential of polyglycerol as a PEG alternative for half-life extension of biotherapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available